12月18日，益诺思盘中上涨2.03%，截至10:26，报51.36元/股，成交4598.80万元，换手率1.00%，总市 值72.41亿元。 益诺思所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：次新股、CRO概念、 央企改革、融资融券、细胞治疗等。 截至9月30日，益诺思股东户数4849.00，较上期减少9.97%；人均流通股18703股，较上期增加 257.28%。2025年1月-9月，益诺思实现营业收入5.71亿元，同比减少35.33%；归母净利润-1478.81万 元，同比减少111.14%。 分红方面，益诺思A股上市后累计派现4511.35万元。 机构持仓方面，截止2025年9月30日，益诺思十大流通股东中，汇添富医药保健混合（470006）位居第 九大流通股东，持股112.15万股，为新进股东。华夏稳盛混合（005450）位居第十大流通股东，持股 93.05万股，为新进股东。工银医疗保健股票（000831）、工银战略转型股票A（000991）、嘉实医药健 康股票A（005303）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流入280.39万元，特大单买 ...

Core Viewpoint - Shanghai Yinos Biotechnology Co., Ltd. has been awarded the "2025 Most Socially Responsible Listed Company Award" for its outstanding practices in social responsibility and professional service capabilities, highlighting its deep accumulation and core value in the CRO professional segment [1][3] Company Overview - Yinos is a comprehensive R&D service (CRO) company specializing in non-clinical research services for biomedicine, adhering to the core values of "science-led, quality-first, integrity, and win-win cooperation" [3] - The company focuses on major national biomedicine development needs and plays a significant role in drug evaluation services, contributing to the high-quality development of the biomedicine industry [3] Business Performance - In Q3 2025, Yinos achieved operating revenue of 195 million yuan, a quarter-on-quarter increase of 17.71%, maintaining a steady growth trend [4] - The company saw a 29.37% year-on-year increase in new order amounts, with significant growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA), which rose by 30.71% and 23.06% respectively [4] Market Position and Strategy - Yinos is positioned as a leading enterprise in the CRO industry, benefiting from a high-growth cycle and possessing technical advantages that meet high-end demand across the entire service chain [4] - The company has established a non-clinical drug metabolism platform compliant with ICH, FDA, and NMPA standards, enhancing its capabilities in radiolabeled isotopes and imaging evaluation research [4] Innovation and International Expansion - Yinos is continuously advancing frontier technologies, particularly in small nucleic acid drugs and CAR-T cell therapy, establishing a comprehensive technical service matrix [5][6] - The company has expanded its international market presence, with significant growth in new order amounts from overseas, enhancing its brand influence and recognition [6] Future Outlook - The award received is not only a recognition of past achievements but also an expectation for future development, as CRO companies play an increasingly important role in new drug development [6] - Yinos aims to leverage this award to strengthen its professional advantages while actively fulfilling social responsibilities, contributing to the high-quality development of China's biomedicine industry [6]

证券之星消息，12月12日医疗服务板块较上一交易日上涨1.17%，益诺思领涨。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出2.4亿元，游资资金净流入1.35亿元，散户资金净 流入1.05亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | | 5.03 Z | 30.20% | -2.10 Z | -12.62% | -2.93 Z | -17.58% | | 300015 | 爰尔眼科 | | 5317.94万 | 8.82% | -6481.96万 | -10.74% | 1164.02万 | 1.93% | | 300759 | 康龙化成 | | 3575.66万 | 3.45% | -2598 ...

Investment Rating - The report maintains a "Buy" rating for certain stocks in the CXO sector, indicating a positive outlook for the industry [58]. Core Insights - The global market is showing signs of recovery, with domestic financing on the rise, particularly in the healthcare sector. In Q3 2025, global financing reached $20.6 billion, marking a 39% increase and the highest in nearly four years. Domestic financing also surged to 18.2 billion yuan, up 97% [2][21]. - The IPO landscape is experiencing a divergence, with overseas markets facing challenges while domestic IPOs are rebounding. The domestic biotech IPOs have seen significant growth, with a 665% year-on-year increase in fundraising [30][34]. - The research and development sector is under pressure globally, but domestic R&D is showing rapid improvement, with new clinical trials reaching historical highs. In the first eleven months of 2025, the number of new clinical trials in China increased by 20% [41][52]. Summary by Sections Financing Sector - Global financing in the healthcare sector is recovering, with Q3 2025 showing a significant rebound. The total financing for the first ten months of 2025 has already surpassed the entire year of 2024 [14][21]. - Domestic financing trends mirror global patterns, with a notable increase in Q3 2025, indicating a clear upward trajectory [21][22]. IPO Trends - The overseas IPO market is stabilizing after a downturn, while domestic IPOs are experiencing a resurgence, particularly in the biotech sector, driven by a favorable secondary market [30][34]. - The first eleven months of 2025 saw a dramatic increase in fundraising from domestic biotech IPOs, highlighting a strong recovery [34][36]. R&D Developments - Globally, the number of new clinical trials is declining, but the domestic market is witnessing a significant turnaround, with new drug IND applications showing stability and growth [41][47]. - The number of new clinical trials in China has reached a historical high, with a notable increase in Phase II trials, indicating a robust pipeline for future drug development [52][53].

证券之星消息，12月5日医疗服务板块较上一交易日下跌0.03%，ST中珠领跌。当日上证指数报收于 3902.81，上涨0.7%。深证成指报收于13147.68，上涨1.08%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 10.77 | 10.01% | 51.19万 | 5.31亿 | | 920670 | 数字人 | 15.35 | 3.23% | 3.19万 | 4843.18万 | | 688710 | 益诺思 | 41.99 | 2.89% | 1.38万 | 5757.13万 | | 301096 | 百诚医药 | 54.49 | 2.48% | 2.61万 | 1.41亿 | | 301267 | 华屋眼科 | 18.90 | 2.27% | 6.22万 | 1.17亿 | | 002622 | 皓宸医疗 | 3.37 | 2.12% | 19.61万 | 6549.95万 | | 002173 | 创新医疗 | 22 ...

证券日报网讯12月2日，益诺思在互动平台回答投资者提问时表示，为遵循信息披露的公平原则，公司 会在定期报告中披露对应时点的股东信息。 ...

Core Viewpoint - The medical services sector experienced a decline of 2.05% on December 2, with Yinosh leading the drop. The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with ST Zhongzhu closing at 2.95, up 3.51%, and Yinosh closing at 41.58, down 7.27% [1][2]. - The total net outflow of main funds in the medical services sector was 9.53 billion yuan, while retail investors saw a net inflow of 6.87 billion yuan [2][3]. Group 2: Individual Stock Analysis - ST Zhongzhu had a trading volume of 1.27 million hands and a transaction amount of 372 million yuan, while Yinosh had a trading volume of 19,500 hands and a transaction amount of 82.48 million yuan [1][2]. - The stock performance varied, with some stocks like Innovation Medical and Dean Diagnostics showing slight declines, while others like ST Zhongzhu showed gains [1][2]. Group 3: Fund Flow Analysis - Main funds showed a net inflow in stocks like Innovation Medical (63.01 million yuan) and Dean Diagnostics (20.61 million yuan), while there were net outflows in several other stocks [3]. - Retail investors contributed to the net inflow in stocks like Innovation Medical and Dean Diagnostics, despite overall sector outflows [3].

Group 1 - The major shareholder, Zhangjiang Biopharmaceutical Base Development Co., Ltd., holds 11,020,753 shares, accounting for 7.82% of the total share capital of the company [1] - Zhangjiang Biopharmaceutical Base plans to reduce its holdings by up to 1,409,796 shares, which is no more than 1.00% of the total share capital, within three months after the announcement [1] - The reduction will be executed through centralized bidding, and the selling price will be determined by market conditions [1][2] Group 2 - The major shareholder has made commitments regarding the holding period and reduction methods, including a lock-up period of 12 months for shares held before the IPO and 36 months for shares obtained through capital increase [2][3] - The reduction plan is consistent with previous commitments made by the major shareholder [4] - The company confirms that the reduction will not lead to a change in control and will not significantly impact the company's ongoing operations [5]

Core Viewpoint - The company announced the appointment of two new vice presidents, Li Yan and Tang Napin, by the board of directors [1] Group 1 - The board of directors approved the hiring of Li Yan as vice president [1] - The board of directors approved the hiring of Tang Napin as vice president [1]

Core Points - Yinos's announcement on November 28 indicates that Zhangjiang Biopharmaceutical Base holds 11,020,753 shares of Yinos, representing 7.82% of the total share capital [2] - Zhangjiang Biopharmaceutical Base plans to reduce its holdings by up to 1,409,796 shares, which is no more than 1.00% of the total share capital, within three months after the announcement [2] - The reduction will be executed through centralized bidding and will not exceed 1.00% of the total shares within any consecutive 90-day period [2]